As the first empirical attempt, we screened the CMap database with the FXS-associated transcriptome signature and identified trifluoperazine as a therapeutic reagent to treat symptoms in the Fmr1 KO mice (Ding et al., 2020b). The gene discussed is FMR1; the disease is fragile X syndrome.